Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vaskar Saha

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Haematology|December 4, 2018
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trialAndrea Biondi, Virginie Gandemer, Paola De Lorenzo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2021
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsCornelia Eckert, Catriona Parker, Anthony V Moorman, et al.
Cancer|July 7, 2023
Development of EPAT: An assessment tool for pediatric hematology/oncology training programsDaniel C Moreira, Monika L Metzger, Federico Antillón-Klussmann, et al.
JAMA|March 2, 2021
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialFranco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
Addressing the Global Diagnostics Gap for Childhood Leukemias: A Global, Multisite Type 2 Hybrid Validation Study of Nanopore-based Adaptive Sampling Whole Genome SequencingThomas B Alexander, Rubina Islam, Javeria Aijaz, et al.
Leukemia|December 9, 2022
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALLFranco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al.
The New England Journal of Medicine|April 13, 2012
Outcomes after induction failure in childhood acute lymphoblastic leukemiaMartin Schrappe, Stephen P Hunger, Ching-Hon Pui, et al.
Digestive Diseases and Sciences|February 5, 2026
An Annotated Living Organoid Biobank for Studying Gallbladder Diseases and Drug ResponsesAnkita Dutta, Nandita Chowdhury, Akshaya Vijayan Selvarajan, et al.
Blood|May 28, 2016
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemiaJulie A E Irving, Amir Enshaei, Catriona A Parker, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Haematology|December 4, 2018
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trialAndrea Biondi, Virginie Gandemer, Paola De Lorenzo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2021
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsCornelia Eckert, Catriona Parker, Anthony V Moorman, et al.
Cancer|July 7, 2023
Development of EPAT: An assessment tool for pediatric hematology/oncology training programsDaniel C Moreira, Monika L Metzger, Federico Antillón-Klussmann, et al.
JAMA|March 2, 2021
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical TrialFranco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al.
Medrxiv : the Preprint Server for Health Sciences|June 4, 2026
Addressing the Global Diagnostics Gap for Childhood Leukemias: A Global, Multisite Type 2 Hybrid Validation Study of Nanopore-based Adaptive Sampling Whole Genome SequencingThomas B Alexander, Rubina Islam, Javeria Aijaz, et al.
Leukemia|December 9, 2022
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALLFranco Locatelli, Gerhard Zugmaier, Carmelo Rizzari, et al.
The New England Journal of Medicine|April 13, 2012
Outcomes after induction failure in childhood acute lymphoblastic leukemiaMartin Schrappe, Stephen P Hunger, Ching-Hon Pui, et al.
Digestive Diseases and Sciences|February 5, 2026
An Annotated Living Organoid Biobank for Studying Gallbladder Diseases and Drug ResponsesAnkita Dutta, Nandita Chowdhury, Akshaya Vijayan Selvarajan, et al.
Blood|May 28, 2016
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemiaJulie A E Irving, Amir Enshaei, Catriona A Parker, et al.
Haematologica|October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologiesGiovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
Pageof 9